GlassScriptPhysician profile
Michaela Lau
NPI 1598531261
$1,539.49
in general payments reported to CMS, 2019-2025
12 companies · $377 in 2025
The $377 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $1,163 · 2025: $377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,440 · Education: $99.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,440.23 |
| Education | $99.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $401.18 | 2024-2025 | Skyrizi, Rinvoq |
| Galderma Laboratories, L.P. | $220.63 | 2024-2025 | Nemluvio |
| Genzyme Corporation | $210.82 | 2024 | |
| Amgen INC. | $204.73 | 2024-2025 | Otezla, Otezla |
| Regeneron Healthcare Solutions, INC. | $202.72 | 2024-2025 | Dupixent, Libtayo |
| Mallinckrodt Hospital Products INC. | $109.48 | 2024-2025 | Acthar |
| Incyte Corporation | $45.65 | 2024 | Opzelura |
| Arcutis Biotherapeutics, INC. | $44.02 | 2025 | Zoryve |
| Leo Pharma INC. | $33.33 | 2024 | Adbry |
| Organon LLC | $28.18 | 2025 | Vtama |
| Verrica Pharmaceuticals INC. | $21.37 | 2024 | Ycanth |
| Janssen Biotech, INC. | $17.38 | 2025 | Tremfya |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michaela Lau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.